These criteria included:
Severity of the disease, including duration of disease, average size of lesions and number of lesions per patient and severity of scars
Lack of response to available drugs
The overall incidence and prevalence of the disease (based on available data)
Sequelae of the disease, including leishmaniasis recidivans (a long-lasting relapsing form of CL often located on the face) and mucosal disease
Public health aspects, including the impact of treatment of individuals on control of transmission of Leishmania spp, the etiological agent (s) of leishmaniasis
Lack of major efforts in drug development
|